• PAD4-IN-2 TFA: Transforming Tumor-Targeted NET Inhibition

  2026-06-16

  This thought-leadership article explores how PAD4-IN-2 TFA, a meta-phenylboronic acid–modified PAD4 inhibitor, leverages innovative tumor-targeting to disrupt the PAD4–H3cit–NET axis, reshape the tumor immune microenvironment, and set new standards for translational cancer research. Grounded in mechanistic insights and evidence from recent studies, it delivers practical guidance for experimental design and positions PAD4-IN-2 TFA as a next-generation tool for cancer biology.

• Gap26 Connexin 43 Mimetic Peptide: Precision in Gap Junction

  2026-06-15

  Gap26, a selective connexin 43 mimetic peptide, enables targeted disruption of intercellular signaling in vascular, neural, and inflammatory models. Its validated protocols, high solubility, and proven efficacy in modulating calcium and ATP fluxes distinguish it as the peptide of choice for advanced gap junction studies.

• Ivermectin in Advanced Parasitology Research: Protocols & In

  2026-06-15

  Ivermectin’s role as a broad-spectrum anti-parasitic extends beyond traditional treatment, driving precision parasitology workflows and innovative screening strategies. This article presents rigorous protocol parameters, troubleshooting insights, and cross-domain lessons inspired by cutting-edge tumor biology, helping researchers maximize the translational impact of Ivermectin from bench to drug development.

• Gap19: Advancing Selective Connexin 43 Hemichannel Blockade

  2026-06-14

  Explore how Gap19, a selective connexin 43 hemichannel blocker, is redefining neuroimmune research with unparalleled specificity and translational insight. This article uniquely examines practical assay design, mechanistic selectivity, and recent evidence on Cx43-mediated macrophage polarization.

• BMS 309403: Advanced FABP4 Inhibitor Workflows in Atheroscle

  2026-06-13

  BMS 309403 enables precise, selective inhibition of FABP4, unlocking advanced experimental designs for dissecting lipid metabolism and inflammation in cardiovascular and metabolic disease models. This article translates the latest mechanistic findings into actionable protocols, troubleshooting insights, and future research directions for researchers seeking to maximize the translational impact of their studies.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-06-12

  Wang et al. reveal that the METTL16-SENP3-LTF axis confers ferroptosis resistance and promotes tumorigenesis in hepatocellular carcinoma (HCC) by fine-tuning iron metabolism and m6A RNA modifications. These mechanistic insights open new avenues to sensitize HCC to ferroptosis-based therapies, highlighting the translational potential of iron chelation strategies.

• Nelfinavir Mesylate: Precision HIV-1 Protease Inhibitor in R

  2026-06-12

  Nelfinavir Mesylate delivers more than robust HIV-1 protease inhibition—it offers a dual toolkit for both antiviral and ferroptosis pathway studies. Its clinical-grade potency, bioavailability, and unique action on the DDI2-NFE2L1 axis make it an indispensable asset for experimental innovation.

• L-Glutathione Reduced in Redox and GST Workflows: Applied Ad

  2026-06-11

  L-Glutathione Reduced empowers redox biology and affinity chromatography with precision, reproducibility, and translational impact. Discover advanced workflow optimizations, troubleshooting strategies, and how recent mechanistic insights in cancer metabolism translate into practical protocols.

• Phos binding reagent (Phosbind) acrylamide for SDS-PAGE Phos

  2026-06-11

  Phos binding reagent (Phosbind) acrylamide enables antibody-free detection and separation of phosphorylated and non-phosphorylated proteins in SDS-PAGE, facilitating protein phosphorylation analysis when phospho-specific antibodies are unavailable or cost-prohibitive. It is best suited for proteins within the 30–130 kDa range under neutral pH conditions. It should not be used outside these parameters or for long-term reagent storage.

• Optimizing Cell Signaling with Gap26 Connexin 43 Mimetic Pep

  2026-06-10

  This article delivers scenario-driven guidance for leveraging Gap26 (Val-Cys-Tyr-Asp-Lys-Ser-Phe-Pro-Ile-Ser-His-Val-Arg) Connexin 43 Mimetic Peptide (SKU A1044) in cell viability and signaling assays. Through evidence-based Q&A, it addresses reproducibility, workflow compatibility, and data interpretation challenges, linking to validated protocols and recent peer-reviewed research.

• Indomethacin as a Precision Tool for Membrane and Adipocyte

  2026-06-10

  Explore how Indomethacin, a nonsteroidal anti-inflammatory drug, enables high-resolution research into membrane microdomains and beige adipocyte differentiation. This article delivers advanced protocol guidance and uniquely connects membrane physics with metabolic research.

• Risedronate Sodium: FPPS Inhibitor Workflows for Bone & Canc

  2026-06-09

  Risedronate Sodium is redefining bone metabolism and cancer research through precise FPPS inhibition, advanced delivery systems, and robust in vitro and in vivo protocols. This article unpacks optimized workflows, troubleshooting tactics, and comparative insights to empower researchers tackling osteoporosis, emphysema, and tumor cell biology.

• Bifendate (DDB): Applied Protocols and Hepatoprotection Adva

  2026-06-09

  Bifendate (DDB) is a synthetic hepatoprotection agent uniquely suited for modeling lipid metabolism and autophagy inhibition in liver disease research. Its robust multi-targeted actions empower both in vitro and in vivo workflows, with optimized dosing and troubleshooting strategies that accelerate translational insights.

• Live-Dead Cell Staining Kit: Quantitative Insights for Diabe

  2026-06-08

  Explore how the Live-Dead Cell Staining Kit enables high-resolution, quantitative cell viability analysis in diabetic wound healing and ROS-related studies. This article delivers advanced scientific insights into Calcein-AM Propidium Iodide staining, bridging core mechanistic understanding with emerging applications.

• Connexin 43/NF-κB Axis Drives AngII-Induced Macrophage Polar

  2026-06-08

  This study reveals how angiotensin II (AngII) promotes pro-inflammatory M1 macrophage polarization via the connexin 43 (Cx43)/NF-κB signaling pathway. The findings clarify a mechanistic link between Cx43 hemichannel activity and immune modulation, with practical implications for targeting Cx43 in inflammatory and cardiovascular research.

499 records 11/34 page Previous Next First page 上5页 1112131415 下5页 Last page